Tenascin-C deficiency ameliorates alzheimer's disease-related pathology in mice

Neurobiology of Aging

Volumn 34, Issue 10, 2013, Pages 2389-2398

  Xie, Kan ^a   Liu, Yang ^a   Hao, Wenlin ^a   Walter, Silke ^a   Penke, Botond ^b   Hartmann, Tobias ^a   Schachner, Melitta ^c   Fassbender, Klaus ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF SZEGED   (Hungary)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

A ; Alzheimer's disease; Inflammation; Neurodegeneration; Tenascin C

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; POSTSYNAPTIC DENSITY PROTEIN 95; TENASCIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NERVE CELL; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING;

AΒ; ALZHEIMER'S DISEASE; INFLAMMATION; NEURODEGENERATION; TENASCIN-C;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; INFLAMMATION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MICROGLIA; MOLECULAR TARGETED THERAPY; TENASCIN; UP-REGULATION;

EID: 84879882439     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.04.013     Document Type: Article

References (47)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., Schwartz M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11784-11789.
3. Cameron B., Tse W., Lamb R., Li X., Lamb B.T., Landreth G.E. Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. J.Neurosci. 2012, 32:15112-15123.
4. Chevalier X., Claudepierre P., Groult N., Godeau G.J. Influence of interleukin 1 beta on tenascin distribution in human normal and osteoarthritic cartilage: a quantitative immunohistochemical study. Ann. Rheum. Dis. 1996, 55:772-775.
5. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J.Biol. Chem. 2001, 276:21562-21570.
6. Chiquet-Ehrismann R., Chiquet M. Tenascins: regulation and putative functions during pathological stress. J.Pathol. 2003, 200:488-499.
7. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J.Neuroinflammation 2006, 3:27.
8. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J.Biol. Chem. 2002, 277:32046-32053.
9. Dityatev A., Seidenbecher C.I., Schachner M. Compartmentalization from the outside: the extracellular matrix and functional microdomains in the brain. Trends Neurosci. 2010, 33:503-512.
10. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
11. Evers M.R., Salmen B., Bukalo O., Rollenhagen A., Bösl M.R., Morellini F., Bartsch U., Dityatev A., Schachner M. Impairment of L-type Ca2+ channel-dependent forms of hippocampal synaptic plasticity in mice deficient in the extracellular matrix glycoprotein tenascin-C. J.Neurosci. 2002, 22:7177-7194.
12. Ferhat L., Chevassus au Louis N., Jorquera I., Niquet J., Khrestchatisky M., Ben-Ari Y., Represa A. Transient increase of tenascin-C in immature hippocampus: astroglial and neuronal expression. J.Neurocytol. 1996, 25:53-66.
13. Fassbender K., Walter S., Kuehl S., Landmann R., Ishii K., Bertsch T., Stalder A.K., Muehlhauser F., Liu Y., Ulmer A.J., Rivest S., Lentschat A., Gulbins E., Jucker M., Staufenbiel M., Brechtel K., Walter J., Multhaup G., Penke B., Adachi Y., Hartmann T., Beyreuther K. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J. 2004, 18:203-205.
14. Fawver J.N., Schall H.E., Petrofes Chapa R.D., Zhu X., Murray I.V. Amyloid-β metabolite sensing: biochemical linking of glycation modification and misfolding. J.Alzheimers Dis. 2012, 30:63-73.
15. Garcion E., Faissner A., ffrench-Constant C. Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration. Development 2001, 128:2485-2496.
16. Garcion E., Halilagic A., Faissner A., ffrench-Constant C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development 2004, 131:3423-3432.
17. Goh F.G., Piccinini A.M., Krausgruber T., Udalova I.A., Midwood K.S. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J.Immunol. 2010, 184:2655-2662.
18. Grilli M., Ribola M., Alberici A., Valerio A., Memo M., Spano P. Identification and characterization of a kappa B/Rel binding site in the regulatoryregion of the amyloid precursor protein gene. J.Biol. Chem. 1995, 270:26774-26777.
19. Grimm M.O., Kuchenbecker J., Grösgen S., Burg V.K., Hundsdörfer B., Rothhaar T.L., Friess P., de Wilde M.C., Broersen L.M., Penke B., Péter M., Vígh L., Grimm H.S., Hartmann T. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J.Biol. Chem. 2011, 286:14028-14039.
20. Gutowski N.J., Newcombe J., Cuzner M.L. Tenascin-R and C in multiple sclerosis lesions: relevance to extracellular matrix remodelling. Neuropathol. Appl. Neurobiol. 1999, 25:207-214.
21. Hao W., Liu Y., Liu S., Walter S., Grimm M.O., Kiliaan A.J., Penke B., Hartmann T., Rübe C.E., Menger M.D., Fassbender K. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain 2011, 134:278-292.
22. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., Staufenbiel M., Li R., Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J.Cell Biol. 2007, 178:829-841.
23. Hsia H.C., Schwarzbauer J.E. Meet the tenascins: multifunctional and mysterious. J.Biol. Chem. 2005, 280:26641-26644.
24. Jana M., Palencia C.A., Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J.Immunol. 2008, 181:7254-7262.
25. Lim J.E., Kou J., Song M., Pattanayak A., Jin J., Lalonde R., Fukuchi K. MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am. J. Pathol. 2011, 179:1095-1103.
26. Liu S., Liu Y., Hao W., Wolf L., Kiliaan A.J., Penke B., Rübe C.E., Walter J., Heneka M.T., Hartmann T., Menger M.D., Fassbender K. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. J.Immunol. 2012, 188:1098-1107.
27. Liu Y., Walter S., Stagi M., Cherny D., Letiembre M., Schulz-Schaeffer W., Heine H., Penke B., Neumann H., Fassbender K. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005, 128:1778-1789.
28. Ma T.C., Campana A., Lange P.S., Lee H.H., Banerjee K., Bryson J.B., Mahishi L., Alam S., Giger R.J., Barnes S., Morris S.M., Willis D.E., Twiss J.L., Filbin M.T., Ratan R.R. Alarge-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzein as a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway. J.Neurosci. 2010, 30:739-748.
29. Mackie E.J., Tucker R.P. The tenascin-C knockout revisited. J.Cell. Sci. 1999, 112:3847-3853.
30. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
31. Mettouchi A., Cabon F., Montreau N., Dejong V., Vernier P., Gherzi R., Mercier G., Binétruy B. The c-Jun-induced transformation process involves complex regulation of tenascin-C expression. Mol. Cell. Biol. 1997, 17:3202-3209.
32. Midwood K., Sacre S., Piccinini A.M., Inglis J., Trebaul A., Chan E., Drexler S., Sofat N., Kashiwagi M., Orend G., Brennan F., Foxwell B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat. Med. 2009, 15:774-780.
33. Naert G., Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J.Neurosci. 2011, 31:6208-6220.
34. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34:185-204.
35. Pearson C.A., Pearson D., Shibahara S., Hofsteenge J., Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-beta. EMBO J. 1988, 7:2977-2982.
36. Peter N.R., Shah R.T., Chen J., Irintchev A., Schachner M. Adhesion molecules close homolog of L1 and tenascin-C affect blood-spinal cord barrier repair. Neuroreport 2012, 23:479-482.
37. Piccinini A.M., Midwood K.S. Endogenous control of immunity against infection: tenascin-C regulates TLR4-mediated inflammation via microRNA-155. Cell Rep. 2012, 2:914-926.
38. Reed-Geaghan E.G., Reed Q.W., Cramer P.E., Landreth G.E. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J.Neurosci. 2010, 30:15369-15373.
39. Reed-Geaghan E.G., Savage J.C., Hise A.G., Landreth G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J.Neurosci. 2009, 29:11982-11992.
40. Sambamurti K., Kinsey R., Maloney B., Ge Y.W., Lahiri D.K. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 2004, 18:1034-1036.
41. Sharma S., Yang B., Xi X., Grotta J.C., Aronowski J., Savitz S.I. IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Res. 2011, 1373:189-194.
42. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 2003, 14:133-145.
43. Song M., Jin J., Lim J.E., Kou J., Pattanayak A., Rehman J.A., Kim H.D., Tahara K., Lalonde R., Fukuchi K. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J.Neuroinflammation 2011, 8:92.
44. Taylor J., Pesheva P., Schachner M. Influence of janusin and tenascin on growth cone behavior invitro. J.Neurosci. Res. 1993, 35:347-362.
45. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 2009, 35:352-358.
46. Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., Bode B., Manietta N., Walter J., Schulz-Schuffer W., Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell. Physiol. Biochem. 2007, 20:947-956.
47. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease-a brief review ofthe basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2012, 2:a006346.